⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Open Access

Supplementary Figure S11 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity

Naveen K. Mehta Kavya Rakhra Kristan Meetze Bochong Li Noor Momin Jason Y.H. Chang K. Dane Wittrup Patrick A. Baeuerle Jennifer S. Michaelson

View Full Paper

Ask AI

Bookmark

Share

Key Points

A standardized t-cell gating strategy isolates specific lymphocyte subpopulations, resolving phenotypic markers following CLN-617 exposure.
Flow cytometry analysis defines distinct immune cell clusters across treated tumor preparations, establishing baseline gating parameters for il2.
Consistent gating schemes may enable reproducible quantification of antitumor activity, though external validation across diverse platforms remains necessary.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Flow cytometry analysis reveals a T-cell gating scheme for CLN-617 evaluation, indicating standardized profiling of antitumor activity.

Abstract

T-cell gating scheme for flow cytometry data analysis

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mehta et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e7b6db64358757526c https://doi.org/10.1158/2326-6066.26422439.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S11 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024
2Supplementary Figure S12 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024
3Supplementary Figure S12 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024
4Supplementary Figure S9 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024
5Supplementary Figure S9 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024

More related papers

Supplementary Figure S10 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024
Supplementary Figure S10 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024
Supplementary Figure S13 from CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity2024